For the quarter ending 2026-03-31, LENZ made $1.901M in revenue. -$42.18M in net income. Net profit margin of -2218.83%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 1.901 | -7* | 12.5 | 5 |
| Cost of sales | 1.076 | 0* | - | - |
| Selling, general and administrative | 44.96 | 32* | 27.596 | 12.796 |
| Research and development | 0 | -1* | 3.791 | 9.061 |
| Total operating expenses | 46.036 | 31* | 31.387 | 21.857 |
| Loss from operations | -44.135 | -38* | -18.887 | -16.857 |
| Other income (expense) | 0.003 | -1* | -0.014 | 0.199 |
| Interest income | 2.644 | 4* | 2.201 | 2.246 |
| Total other income, net | 2.647 | 3* | 2.187 | 2.445 |
| Net loss before income taxes | - | -35* | -16.7 | -14.412 |
| Income tax expense | - | 0* | 0 | 0.5 |
| Net loss | -41.488 | -35* | -16.7 | -14.912 |
| Unrealized gain on marketable securities | -0.692 | 0* | 0.189 | -0.085 |
| Comprehensive loss | -42.18 | -35 | -16.511 | -14.997 |
| Basic EPS | -1.32 | -1.168 | -0.59 | -0.53 |
| Diluted EPS | -1.32 | -1.168 | -0.59 | -0.53 |
| Basic Average Shares | 31,352,702 | 29,819,902 | 28,540,519 | 28,079,071 |
| Diluted Average Shares | 31,352,702 | 29,819,902 | 28,540,519 | 28,079,071 |
LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics, Inc. (LENZ)